Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
new people should read posts from past few months. Also go to otcmarkets .com and look at all the form 4's of insider buying during past 24 months. CEO knows how undervalued this is and insiders don't buy to make 20%.
LXRP BREAKOUT
JUST HIT .25 IN CANADA (WHICH = .1884 in USA
The float is so low here this could rip past $1 so quickly
form 4 out Bunka bought another 20K shares
FINALLY SOME VOLUME!!!
thought we might get more follow thru and get over .15
some early action. very nice to see
AGSTF MASSIVE BREAKOUT
AGSTF LXRP LCTC
LOW FLOAT RUNNERS
SRNA AGSTF LXRP KEEP EYE ON
SHOCKED LXRP DOESNT GET MORE ATTENTION
INSIDER BUYING LOW MARKET CAP.
looks like someone wanted out but nice comeback. Hopefully this closes up for day.
these shares on ask @.13 are a gift
yup 2500 shares on canada side at .145 (CAD) 10-5-16
those notes aren't due for a few months. Seems like your trying to scare people into selling. This will break .20 very soon
CEO buys in open market once again!
SRNA AGSTF LXRP
what would blow my mind is volume over 1 million shares
60% of the shares are held by insiders and those shares are held in escrow for 1 year. Can't be sold. This is headed well over $1.
AGSTF BREAKOUT LXRP READY TO GO NEXT
AGSTF BREAKOUT LXRP CHECK OUT
AGSTF I hope some took advantage of this!!!! This has much more room to run.
LXRP keep a close eye on......
This is just the beginning
AGSTF been calling it out NEXT TO RUN LXRP
I think we are going to break out and close above .15
I didn't mean you specifically.
look at the run AGSTF is on you telling me LXRP can't do this
sent via email on their newsletter list
Dear Lexaria Community, Much is happening both within Lexaria Bioscience, and out in the marketplace. Let’s quickly review just one of these events... Last week an article was published on competitor GW Pharmaceuticals (Nasdaq: GWPH) Here is an excerpt from that article: GW Pharmaceuticals (Nasdaq: GWPH) is on a tear. The stock just hit a new all-time high, $132.47. But GW Pharma isn't your average drugmaker. Long-time readers know that this British firm is doing something extraordinary. The company appears to be on track to have the first FDA-approved treatment derived from marijuana. The "drug" is called Epidiolex. It's a highly purified extract of the cannabis plant. Specifically, the molecule it's using is called CBD. And there's a very good reason I've been pounding the table on the potential of this molecule for more than a year. GW Pharmaceuticals' Pop GW Pharma's shares are jumping due to positive late-stage clinical trial data. Most recently announced was a Phase 3 trial for patients with Lennox-Gastaut syndrome, a rare form of childhood epilepsy. Epidiolex at 20 milligrams reduced seizures for 42% of patients. Side effects were generally well-tolerated. This makes the company's third successful Phase 3 trial. Lexaria Bioscience congratulates GW Pharma on their achievements and is thrilled to see the continued advancement and recognition of cannabidiol (CBD) as an effective remedy in controlled studies. Of course it is no surprise that the Lexaria community embraces research into CBD and the flood of positive news being generated around the world as a result of that research. We’ve done research of our own, demonstrating up to 499% higher absorption of CBD across human intestinal cells, when the CBD is delivered with Lexaria’s patent-approved technology. GW Pharma currently has a market cap of around US $3.3 billion dollars. Lexaria has a market cap of about US$7 million dollars. We cannot hope to compete with GW’s research budget; but I’m willing to compare the value and validity of our growing IP (Intellectual Property) portfolio against GW’s or anyone else’s. Lexaria currently has one allowed patent by the USPTO and five more patents pending. Our allowed patent is for the delivery of non psychoactive cannabinoids utilizing our proprietary methodology: obviously including but not limited to CBD. Lexaria Bioscience has demonstrated the effectiveness of its delivery technology through the in vitro study mentioned above; and also through a human volunteer study that showed up to a ~1,000% increase in nitric oxide production after consuming our food products containing CBD utilizing our advanced technology. As well, these increases occurred in as little as 15 minutes after consumption, strongly indicative of first-pass liver metabolism BYPASS – meaning we believe our technology delivers CBD through the lymphatic system and avoids the filtration by of the liver. Human nitric oxide production is widely sought because of its vasodilation qualities: nitric oxide dilates blood vessels and is a biomechanical system utilized by drugs like Viagra; hypertension drugs; and athletes looking to legally boost athletic performance. Lexaria’s technology works across ALL FOUR of the bioavailability barriers: 1) Dramatic improvement in taste to encourage edible consumption; 2) lipophilic protection against stomach acids; 3) preferential absorption across intestinal cell barriers; 4) lymphatic system absorption that bypasses first-pass liver metabolism and filtration. Lexaria is not aware of any other technology that provide benefits across all four of the bioavailability barriers – and that INCLUDES any known tech held by GW Pharma. Come to your own conclusions about Lexaria’s relative value. Lexaria is used to facing challenges and we expect that will to continue. But make no mistake: we believe we have ground breaking technology that upsets the status quo in the marijuana sector but also in pain relief, vitamins, cigarette smoking cessation, and more. We’re working hard and want to make sure you know it! Sincerely, Chris Bunka, Chief Executive Officer
Company update just released
market cap is so low on this. I could easily see this getting in that $2-5 range
AGSTF BLASTOFF
was looking for more volume today
BREAKING OUT
They need to get the word out. Profitable OTC stock with $3+ million cash
This could easily run over $20 again
How do you feel about them? Share structure very favorable.
AGSTF 62% of shares held by insiders are in escrow for 1 year. very low float
it traded a whopping $32K that is not much money for people to be accumulating